Proceedings: AACR Annual Meeting 2021; April 10-15 and May 17-21
Introduction: The presence of high-grade histologic patterns such as micropapillary or solid (MPSol) in patients with lung adenocarcinoma (ADC) is known to have a poor prognosis even if it is not the most predominant subtype. However, since it is difficult to determine the histologic pattern of the entire tumor with a small biopsy sample, there is a growing need for non-invasive biomarkers that can predict the histologic pattern of lung ADC. We developed a deep learning (DL)-based model as a radiomic biomarker that predicts high-grade ADC patterns and validated by applying it to the independent clinical dataset.
Methods: A total of 290 early lung ADCs (from 275 patients) underwent curative surgical resection recruited from Samsung Medical Center were retrospectively analyzed as a training dataset. We developed a 3D convolutional DL model called morphologic-view context-view 3D network (MC3DN). Our model was developed to focus on morphologic characteristics of target lesion with contexture information observed around the lesion. Additional information about pathologic size and segmentation were trained together. An independent dataset of 416 patients with advanced lung cancer who underwent neoadjuvant concurrent chemoradiation therapy (CCRT) or definitive CCRT was analyzed to assess the prognostic performance of our model.
Results: Of the training set, 54 (18.6%) lesions had MPSol pattern as the most or second predominant histologic pattern in the pathologic specimen. For the prediction of the presence of MPSol pattern, the area under the curve (AUC) value of the baseline MC3DN was 0.77. When training the model with pathologic size and segmentation together through multi-task learning, the AUC value increased to 0.80. When applied to the validation set, a high probability of MPSol estimated by DL model was associated with worse overall survival (probability of MPSol > 0.5 vs ≤ 0.5; 5-year OS rate 59.0% vs 73.6%, p=0.007). The subgroup with a high probability of MPSol showed 1.78 folds high risk for death (95% CI 1.17-2.72, p = 0.008). It was also significantly associated with overall survival after adjusting for other prognostic factors including age, sex, smoking, ECOG, and TNM stage (HR 1.61, 95% CI 1.05-2.47, p=0.029).
Conclusion: MC3DN model through CT images could be useful in estimating any high-grade histologic pattern of lung ADCs and predicting clinical outcomes of patients with advanced lung cancer who underwent neoadjuvant or definitive CCRT. This model is also applied to inoperable patients and could be used to establish a treatment plan.
Yeonu Choi, Jaehong Aum, Seunghwan Shin, Chan-Young Ock, Se-Hoon Lee, Hong Kwan Kim, Jhingook Kim, Ho Yun Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, Lunit Inc., Seoul, Korea, Republic of, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Abstract: Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma.
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Abstract : AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer